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Abstract 
 
Prediction or prognostication is at the core of modern evidence-based medicine. 
Prediction of overall mortality and cardiovascular disease can be improved by a 
systematic evaluation of measurements from large-scale epidemiological studies or by 
using nested sampling designs to discover new markers from omics technologies. 
In study I, we investigated if prediction measures such as calibration, discrimination 
and reclassification could be calculated within traditional sampling designs and which 
of these designs were the most efficient. We found that is possible to calculate 
prediction measures by using a proper weighting system and that a stratified case-
cohort design is a reasonable choice both in terms of efficiency and simplicity. 
In study II, we investigated the clinical utility of several genetic scores for incident 
coronary heart disease. We found that genetic information could be of clinical value 
in improving the allocation of patients to correct risk strata and that the assessment of 
a genetic risk score among intermediate risk subjects could help to prevent about one 
coronary heart disease event every 318 people screened. 
In study III, we explored the association between circulating metabolites and incident 
coronary heart disease. We found four new metabolites associated with coronary heart 
disease independently of established cardiovascular risk factors and with evidence of 
clinical utility. By using genetic information we determined a potential causal effect 
on coronary heart disease of one of these novel metabolites. 
In study IV, we compared a large number of demographics, health and lifestyle 
measurements for association with all-cause and cause-specific mortality. By ranking 
measurements in terms of their predictive abilities we could provide new insights 
about their relative importance, as well as reveal some unexpected associations. 
Moreover we developed and validated a prediction score for five-year mortality with 
good discrimination ability and calibrated it for the entire UK population. 
In conclusion, we applied a translational approach spanning from the discovery of 
novel biomarkers to their evaluation in terms of clinical utility. We combined this 
effort with methodological improvements aimed to expand prediction measures in 
settings that were not previously explored. We identified promising novel 
metabolomics markers for cardiovascular disease and supported the potential clinical 
utility of a genetic score in primary prevention. Our results might fuel future studies 
aimed to implement these findings in clinical practice. 
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1 Introduction 
1.1 The concept of prediction or prognostication 
The concept of prediction or prognostication is central to modern evidence-based 
medicine. Clinical prediction models are currently used in primary or secondary 
prevention to predict diseases or unfavourable outcomes or to determine the best 
choice of therapy. Evidence-based medicine will undoubtedly see an increase of these 
tools in the future, together with advancements in the different fields required for their 
development.  
Nevertheless, prediction has always been practiced in medicine as much as prediction 
abilities have always been in the skillset of clinicians. However, the quantification 
and rationalization of what has often been called ‘intuition’ was possible only with the 
advent of data-rich clinical studies and appropriate statistical methodologies. 
Statistics is the backbone of prediction models. Statistical models are suitable for 
combining results obtained from different technologies, such as genetics, proteomics 
or metabolomics into a single predictive equation that returns meaningful information 
for clinicians and patients.  
Importantly, having well-defined statistical models allows rational and shared 
decision-making. Further, such quantifiable decisions can be evaluated at public 
policy levels for planning specific intervention strategies. Finally, information derived 
from prediction models is important to make individuals aware of their conditions in 
order to prevent future diseases. 
Following the pioneering work conducted on participants from the Framigham Heart 
study (FHS) [1], cardiovascular disease research has become the preferred field for 
developing prediction models and studying their utility for decision-making purposes.  
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2 Cardiovascular disease 
2.1 Definition of cardiovascular disease 
The term cardiovascular disease includes diseases of the heart, brain and peripheral 
vessels. Pathological processes affecting the heart may be broadly divided into three 
major categories: 
1. Disease of the cardiac muscle commonly defined as cardiomyopathies.  
2. Disease of the conduction system that lead to disturbance of the heart rhythm, 
called arrhythmias.  
3. Disease affecting the coronary arteries, called atherosclerosis.  
This thesis mainly focuses on the third category, atherosclerotic cardiovascular 
disease, which also includes ischemic stroke, and from now on is referred as CVD. 
2.2 Epidemiology of cardiovascular disease 
CVD, including coronary heart disease (CHD) and stroke remains the leading cause 
of mortality worldwide, accounting for approximately 30% of total mortality [2]. 
Moreover, this unfortunate leadership is expected to last at least to the year 2030 [3]. 
Although there has been a decline in CVD mortality in high-income countries over 
the years, the burden of this disease is increasing as a result of adaptation of a 
Westernized lifestyle in poorer countries with increasing obesity, type 2 diabetes and 
smoking rates (see Figure 1) [4] . 
Finally, the non-fatal CVD events contribute significantly to overall disability, 
estimated by the disability-adjusted life years. In 2010, the total burden of CVD was 
295 millions disability-adjusted life years, reaching an increase of 22.6% compared to 
1990 [5]. 
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Figure 1. World map showing the global distribution of CVD mortality rates (age 
standardized, per 100,000) in males (panel A) and females (panel B) [6]. 
 
2.3 Etiology of cardiovascular disease  
CVD is a multifactorial disease, with a number of modifiable physiological risk 
factors such as high blood pressure [7], high total cholesterol [8], high blood glucose 
[9] and high body mass index (BMI) [10].  
Also modifiable behavioural risk factor play a causal role and include increased 
alcohol use [11], tobacco smoking [12], unhealthy diet [12]  and physical inactivity 
[13]. Finally, familial aggregation of CVD suggests evidence of a genetic 
predisposition [14] and twin studies have reported about 40% heritability of CHD 
mortality [15]. 
A. 
B. 
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2.4 Challenges in cardiovascular disease prevention 
Most of the cardiovascular risk factors where already established before 1975 [16]  
and, in the following decades, improvement in primary prevention, cardiac care  and 
major pharmaceutical drugs have contributed to dramatically decrease CVD mortality 
(see Figure 2) [17].  
Nevertheless, this decrease has not been homogenous between all CVD subtypes. For 
example, an improvement in survival has been observed for myocardial infarction, but 
not for stroke or heart failure. Moreover, although efforts to decrease cholesterol 
levels and smoking have been successful in the United States and Europe over the 
past two decades, prevalence of obesity and type 2 diabetes is on the rise and only 
~1% of individuals in the United States reach what the American Heart Association 
has defined “ideal cardiovascular health” [18, 19].  
Is therefore important, on one side, to identify new strategies (pharmacological or 
behavioural) for reducing the CVD burden in the community and, on the other, to 
identify the right targets for such interventions. Prediction models can be used to 
identify and assign individuals to the best intervention strategy and are therefore a key 
component of the challenge of reducing the CVD burden. 
 
Figure 2. Trends in CVD mortality rates (age standardized) in developed countries 
[6]. 
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3 Prediction models 
3.1 Study design for building prediction models 
Risk prediction and prognosis are inherently longitudinal in nature. Therefore, 
prospective cohort studies with participants followed over time are a natural choice 
for evaluating these aspects. Case-control studies are not suitable to evaluate and 
develop prediction models, while case-cohort and nested case control designs can be 
used, but attention to several methodological aspects needs to be paid [20].  
An optimal study should have a high participation rate and should be conducted in a 
sample of the population for which the prediction model is intended. In addition, the 
study should also be able to follow up patients for both mortality and incidence of the 
disease of interest. Moreover, if the aim is to build a new prediction model, the study 
should preferably collect a large number of reproducible measurements, not necessary 
causally related with the disease. 
3.2 Model performances: Discrimination 
Discrimination relates to how well a prediction model can discriminate those with the 
outcome from those without the outcome. A model that places each individual in the 
class to which he or she truly belongs would be said to have a perfect discrimination.	  
One of the most popular measures of discrimination used in the context of 
dichotomous outcomes is derived from the receiver operating characteristic (ROC) 
curve. The ROC curve is the entire set of possible true and false positive fractions (i.e. 
sensitivity and 1- specificity) attainable by dichotomizing the outcome of interest with 
different thresholds [21]. 
The most widely used summary measure is the area under the ROC curve (AUC), also 
known as the C-statistic. A perfect test, which always assigned individuals to the 
correct outcome, has a AUC value of one. Conversely, an uninformative test, has 
AUC=0.5. The AUC can be interpreted as the probability that a randomly selected 
person with the event has a higher predicted risk than a randomly selected person 
without the event. 
Generalized versions of the AUC for survival analysis have also been developed [22, 
23]. The most commonly used measure is the Harrell’s C-index [24], which measures 
the concordance between the predicted survival time and the actual survival time in 
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pairs of individuals where at least one has experienced the event of interest. 
Finally, differences in AUC or C-index between two models that share all risk factors, 
except for a new marker, can be used to evaluate the improvement in discrimination 
due to the new marker. However, in this setting the AUC has been criticized to be 
insensitive to clinically important risk differences [25]. Moreover, a formal test for 
AUC improvement [26] has been shown to be underpowered compared to more 
common tests to compare nested regression models (e.g. Wald or likelihood-ratio test) 
[27]. 
3.3 Model performances: Calibration 
Calibration measures how closely the predicted risk approaches the observed risk. 
More specifically, it is the agreement between the probability of developing the 
outcome of interest within a certain time-period as estimated by the prediction model 
and the observed outcome frequencies.  
To assess the model’s calibration, a plot of the predicted and observed events (or 
probabilities of events) can be used. Perfect prediction should follow the 45° line. A 
deviation from this line indicates overestimation or underestimation of the true 
number of events. In Figure 3, we report an example of calibration plot obtained from 
study IV. 
This aspect can be formally tested by comparing observed and expected number of 
events in each risk categories as defined by risk deciles. Such 𝜒!  test is called 
Hosmer-Lemeshow test [28]. A similar test for survival data has also been proposed 
(Grønnesby and Borgan goodness-of-fit test) [29].  However, these tests do not 
capture all the potential miscalibration patterns. Moreover, a test might suggest good 
calibration simply due to lack of power.  
Good calibration does not mean good discrimination and vice versa. A model, once 
tested in a different population from the one where it has been developed, can still 
have good discrimination, but the calibration might be poor because the disease 
incidence is different. A processed known as re-calibration can be used to re-fit the 
model to the new population [30]. 
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Figure 3. Example of calibration plot of observed vs. predicted risk obtained from 
study IV. The deciles of risk are represented by the triangles and the dotted lines are 
the loess smoothers. Overlap with the 45° line indicates perfect calibration.  
 
3.4 Reclassification 
An important property of a prediction model is the ability to stratify the population 
into clinically relevant risk categories. A perfect model would assign the entire 
population to the very highest or very lowest risk categories and leave no one in the 
middle categories, in which there are still uncertainties about the appropriate course of 
action.  
Reclassification measures are typically used to evaluate this property when a new risk 
marker is added to a risk prediction model that includes an established set of markers. 
The most commonly used measure of reclassification, net reclassification 
improvement (NRI), was introduced by Pencina and colleagues [31]. This approach 
focuses on reclassification tables constructed separately for individuals with and 
without the event of interest and quantifies the correct movement in categories: 
upwards for those that eventually experience an event and downwards for those that 
do not experience an event. In Figure 4, we report an example of reclassification plot 
and table from study II.  
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NRI is meaningful when risk categories are well defined (e.g. by guidelines) and 
when specific behavioural or pharmacological interventions are available for high-risk 
patients. The NRI has been criticized because it is highly dependent on the number of 
risk categories chosen [32], lacks clinical interpretation [33]  and is difficult to 
interpret in some situations [34].  
 
Figure 4. Reclassification graph and table obtained from study II representing the 
individual risk at 10 years for a model with FHS risk factors vs. individual risk at 10 
years for a model with FHS risk factors + multilocus genetic score (MGRS) for CHD. 
Blue marks are correctly reclassified, red marks are incorrectly reclassified between 
categories of clinical interest (<10%, 10% to 20%, >20%). 
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3.5 Measures of clinical utility 
In addition to evaluate the performances of the prediction model using measures such 
as discrimination and calibration, it is also important to determine if the model is 
clinically useful. The NRI partially tackles this problem by introducing clinically 
meaningful risk categories in the measure assessment. However, it does not touch 
upon the concept of benefit and harm, which are at the core of medical decision-
making [35]. 
Vickers and Elkin proposed a decision-curve analysis as a simple approach to 
quantify the clinical usefulness of a prediction model (or an extension to a model) 
[36]. This method is used to calculate the net benefit, which is the weighted difference 
between benefits and harms (defined as true positive and false positive decisions, 
respectively).  
Rapsomaniki and colleagues introduced a different version of the net benefit, which 
quantifies the number of event-free life years saved per 1,000 people screened. 
Differently from the decision-curve analysis approach, external information, 
including the cost of treatment per person per year and the monetary value of event-
free life years, needs to be included [37].  
Finally, prediction models can be evaluated using health-economic approaches, such 
as Markov chain Monte-Carlo methods [38]. These models can be used to perform 
cohort simulations as well as individual-based microsimulations and require 
numerous external information, which is normally obtained from the literature or 
from existing population-based studies.	  
3.6 Overfitting and validation 
Performance measures that are calculated in the same data sample from which the 
prediction model is developed tend to perform overoptimistically. 
This is simply because the model is designed to fit the data, but becomes less accurate 
when tested in new but similar individuals. This concept is called overfitting. The 
overfitting is greater with a smaller sample size and when a large number of 
measurements are included in the model. 
There are several strategies to control the overfitting and they are traditionally divided 
in internal and external validation.  
Internal validation aims to reduce the overfitting by using the same population that 
generated the model. Split-sample and k-fold cross-validation are commonly used 
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strategies to divide the study in specific subsamples, some of which are used to 
develop the model and the others to validate it. In the case of k-fold cross-validation 
this process is repeated iteratively. 
External validation reduces the overfitting by using individuals that differ in some 
aspects from those in which the model is developed. External validation can be 
applied to individuals collected at a different time points (temporal validation), in 
individuals from a different geographical regions (geographical validation) or in a 
completely separate population, collected by independent investigators. 
3.7 Prediction models in cardiovascular disease 
Starting with the Framingham risk score over 30 years ago [39], the cardiovascular 
disease field has been a fruitful source of prediction models.  
There are several reasons behind this favorable attitude: 
1. Cardiovascular disease is the leading cause of death and therefore a common 
outcome in the population. This makes feasible to plan prospective population-
based studies and to observe enough events within a limited follow-up time (often 
10 years). 
2. Risk factors for cardiovascular disease are well known and easily measurable. 
Those can be combined in a prediction model with relatively high prediction 
performances. 
3. Individuals that are likely to develop a cardiovascular event, as detected by 
prediction models, can be assigned to several preventive strategies, both 
pharmacological and behavioural, without major side effects. 
The original Framingham risk score was developed in 5,209 men and women between 
the ages of 30 and 62 recruited in 1948 from the town of Framingham, Massachusetts. 
The primary outcome was prediction of eight-year CVD and included the following 
risk factors: age, systolic blood pressure, total cholesterol, glucose intolerance, 
cigarette smoking and left ventricular hypertrophy by electrocardiogram [39]. In 
Figure 5, we report the original coefficients published in the 1976 paper, including 
the description on how to calculate the score. 
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Figure 5. Original table from Kannel’s 1976 paper describing a first version of the 
Framingham risk score	  [39]. 
 
Different risk factors have been included in following versions of the score [40, 41] 
and extensions to evaluate the risk of ten-year atrial fibrillation [42], ten-year CHD 
[43], 30-year CVD [44], eight-year diabetes [45], four-year hypertension [46] and ten-
year stroke [47] have also been proposed. 
Several cardiovascular prediction models have been developed in Europe because the 
Framingham risk scores were not entirely suitable to the general European population. 
The SCORE equation has been recommended by the Fifth Joint European Task Force 
on cardiovascular prevention [48]. The QRISK2 algorithm was developed using a 
population-based clinical research database in the UK [49]. A simple PROCAM score 
scheme [50] and a neural network model [51] were developed in Germany. An 
ASSIGN risk score involving family history of CVD was developed in Scotland 
based on the Scottish Heart Health Extended Cohort [52] and finally, a CUORE 
equation was developed in Italy for a low coronary incidence population [53].  
Similarly, other CVD risk models have been constructed elsewhere in the world. A 
MUCA ischemic CVD risk model was developed for the Chinese population [54]. A 
multivariate regression model involving C-reactive protein was developed in Japan 
[55]. A recalibrated Framingham model was investigated in Thailand [56] and a 
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multivariate risk prediction model for CHD was developed in Australia based on the 
Busselton Health Study [57].  
3.8 Prediction models for overall mortality  
Similarly to what done for CVD, prediction models have also been developed for 
overall mortality. Although mortality is a very heterogeneous trait, identification of 
high-risk individuals with reduced life expectancy is important from a public health 
perspective. Guidelines are increasingly incorporating life expectancy as a central 
factor in weighing the benefits and the burdens of tests and treatments.  
For example, the US Preventive Services Task Force recommends routine colorectal 
cancer screening for adults aged 50 to 75 years [58]. One reason for using a 75 year 
old cut-off is that the average life expectancy for 75-year-old US adults (11.1 years in 
2000) is similar to the time to benefit for colorectal cancer screening (10.3 years) 
[59]. In this case, the life expectancy is simply obtained on a population level (e.g. 
from life tables). However, it is clear that life expectancy is heterogeneous among 75 
years old individuals, depending on their individual risk profile, and the calculation of 
life expectancy simply based on age is an oversimplification. Therefore, the use of 
prognostic indices in this setting might improve the decision-making about preventive 
strategies [60]. However, it has also been highlighted that the accuracy and 
generalizability of current prediction tools is low [61].  
There are several reasons why building an appropriate prediction model of overall 
mortality might be challenging: 
1. Mortality is not uniformly distributed across ages. Among younger individuals, 
death due to diseases is a relatively rare event and therefore large population 
studies are needed to gather enough events in a short follow-up time. 
2. Risk factors for overall mortality are heterogeneous and, unlikely those for CVD, 
there is not a consensus regarding which factors to include in a prediction model. 
Comorbidities are important predictors of mortality, but prediction models only 
based on previous diseases or conditions might encounter problems due to 
reporting and diagnostic biases. Lifestyle measurements and biomarkers are 
preferred risk factors, but they are often difficult to collect on large-scale. 
3. The strongest predictors of mortality are often geographical and time-dependent. 
This makes the generalizability of the results challenging, especially if the study 
is not contemporary or representative of the general population. 
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Nevertheless several prediction models for mortality have been developed. The 
Charlson index is the one of the most popular comorbidities-based tools to predict 10-
year mortality [62].  
Several prediction models have been developed in older adults. A recent review by 
Yourman and colleagues summarized these models in terms of potential for bias, 
generalizability, and accuracy [61]. Overall, the authors identified 16 validated 
prediction models. Eight were developed in hospital patients, six in community-
dwelling patients and two in nursing home patients. Prediction models were mostly 
developed in participants from US, while only four from Europe. Only two models 
were validated by investigators not involved in the studies’ development, and no 
model was prospectively tested and found to be accurate in a large diverse sample. 
They concluded that no study was completely free from potential sources of bias. 
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4 Omics and prediction 
4.1 Genomics  
Genomics has known a phase of intense development in the past years. The first 
sequence of the human genome in 2001 [63, 64] and the subsequent HapMap Project 
[65] have helped to shed light into the characteristics and the haplotype structure of 
the human genome and led to the explosion of genome-wide association studies 
(GWAS). The assumption behind these studies is the so-called ‘common disease–
common variant’ hypothesis, which posited that common genetic variants could have 
a role in the etiology of common diseases [66]. Thus, by an unbiased scan of common 
variants in the genome one could, in principle, pinpoint key genes and help to outline 
underlying mechanisms.  
Specifically, GWASs take advantage of the principle of linkage disequilibrium at 
population level to identify genetic markers to tag a haplotype, and the number of 
such tagging markers is much smaller than the total number of segregating variants in 
the population. With this strategy the cost-per-sample can be reduced and a large 
number of individuals can be genotyped for these tagging markers, also called single 
nucleotide polymorphisms (SNPs). For example, a selection of approximately 
500,000 common SNPs in the human genome is sufficient to tag common variation. 
Simple statistical models combined with a tight control for the number of false-
positives (often using a P-value < 10-8 to declare significance) and replication in 
external populations can be used to compare cases of a specific disease and control in 
several thousands individuals across hundred thousands to millions SNPs. The large 
number of individuals is needed in order to detect the small effect of SNPs on the 
disease with sufficient statistical confidence.  
In the recent years, hundreds of these studies has been conducted and have identified 
SNPs associated with more than 1,000 traits or diseases. If, on one side, these 
discoveries can be used to understand the biological basis of diseases and to 
potentially develop new pharmacologic therapies, on the other, results from GWASs 
have the potential to be useful for disease prediction. 
However, given the small effect sizes observed for most of these associations and the 
relative small portion of the heritability explained, it has been argued that the clinical 
impact of genetic risk prediction using common SNPs is limited [67-70]. Moreover, 
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several pitfalls in making predictions of common diseases or complex traits from 
genetics data have been identified. These include errors in estimating the effect size of 
the markers, inappropriate statistical methods, lack of validation, overfitting and 
population stratification [71].  
4.2 Metabolomics 
Metabolomic profiling, or metabolomics, can be described as a holistic approach to 
the study of low-weight molecules (<1,500 Daltons) called metabolites. These 
molecules are produced by chemical processes in the body (i.e. metabolism) or from 
exogenous sources (e.g. diet, drugs, xenobiotics or gut-host co-metabolism). 
Metabolites are often measured in blood or urine, but they can also be detected in 
saliva, breath or any of the approximately 500 different histological cell types in the 
human body [72]. 
Improvements in instrumental technologies and advances in bioinformatics tools have 
provided the possibility to perform metabolomics on large prospective 
epidemiological studies with thousands of individuals and hundreds of phenotypes 
[73].  
The two main approaches to perform large-scale metabolomics studies are nuclear 
magnetic resonance (NMR) spectroscopy or mass spectrometry (MS). NMR has high 
reproducibility, requires little sample preparation and the cost per sample is relatively 
low. However, it is less sensitive, meaning that fewer metabolites can be detected. 
Mass spectrometry allows the detection of a larger number of metabolites, but it is 
less reproducible, more platform dependent and the analysis of the generated data is 
more complex. 
NMR and MS can run either in targeted or non-targeted mode. The targeted approach 
relies on the measurement of a specific subset of metabolites, typically focusing on 
pathways of interest. However, with this approach a large number of disease-related 
metabolites are likely to be missed. The non-targeted approach has the advantage to 
simultaneously measure as many metabolites as possible from a biological sample. 
This approach however requires a post-hoc annotation of the results and, often, the 
chemical structure of some metabolites cannot be resolved.  
Disease prediction using metabolomics is a relatively new field and few promising 
studies have been conducted to investigate this aspect in relation to cardiovascular 
disease [74-76]. 
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4.3 Challenges in measuring omics technology on large scale: The role 
of sampling designs 
Recent technological developments have allowed researchers to assess thousands of 
genetic markers, proteins, and metabolites in small amounts of biologic specimens. In 
parallel, several new large initiatives in different countries have started to collect 
baseline information and biological specimens from hundreds of thousands of 
individuals [77, 78]. The combination of huge study samples and high costs for these 
new technologies makes it unfeasible to measure these new markers on an entire 
study population, so there is a clear need for efficient study designs. 
Researchers are often interested in selecting from an on-going prospective cohort 
study all the cases of a disease and an appropriate set of controls. Thus, the markers of 
interest are measured only in this subsample of participants. Commonly used 
sampling designs are: 
1. Case cohort. All cases of a specific disease or of multiple diseases are collected 
and controls are sampled from original cohort (subcohort) independently of the 
definition of the cases. 
2. Nested case-control. All cases for one specific disease are collected and controls 
are sampled from individuals at risk at the times when cases are identified. 
These sampling designs have been used in several studies [79-82] to investigate the 
prediction abilities of new cardiovascular markers above established risk factors. 
Nevertheless, methodological investigations regarding the appropriate way to derive 
measures of prediction performances within a sampling design setting are lacking.  
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5 Aims 
The general aim of this thesis is to evaluate established measurements and novel 
markers derived from omics technologies in terms of their ability to predict 
cardiovascular disease and overall mortality, as well as to investigate methodological 
aspects related to the use of prediction metrics in epidemiological studies.  
The specific aims of this thesis, each corresponding to one of its four component 
papers, are: 
• To investigate the ability to adequately estimate individual risk and risk 
prediction metrics in unstratified and stratified (matched) case-cohort and nested 
case-control designs. 
• To investigate the clinical utility of several genetic scores for CHD.  
• To discover new markers of CHD by analysing circulating metabolites and to 
determine if these metabolites can improve CHD prediction beyond established 
risk factors. 
• To compare a large number of potential predictors of five-year mortality and to 
develop and validate a prediction score for five-year mortality using only self-
reported information. 	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6 Study populations 
6.1 Swedish Twin Registry: Overview 
The Swedish Twin Registry is a nation-wide register including over 194,000 Swedish 
twins born from 1886 to 2008 [83]. Since 2004, all identified nine-year-old have been 
contacted and invited to participate to an ongoing study [84]. Before 2004, the twins 
were contacted at various ages depending on birth-year cohorts. Over the past ten-
years, DNA information was obtained from 45,000 twins, 15,000 of which also 
provided blood samples.  
6.2 Swedish Twin Registry: TwinGene 
TwinGene is a longitudinal study nested within the Swedish Twin Register initiated to 
examine associations between genetic factors and cardiovascular disease in Swedish 
twins. Twins born before 1958 and who has participated in a telephone screening 
between 1998 and 2002 were re-contacted between April 2004 and December 2008. 
Health and medication data were collected from self-reported questionnaires, and a 
blood sampling kit was mailed to the subject who then contacted a local health care 
center for blood sampling and a health check-up. Contacts were allowed on Monday 
to Thursday mornings (not the day before a national holiday), to ensure that the 
sample would reach the KI Biobank in Stockholm the following day by over night 
mail. The participants were instructed to fast from 8 PM (20:00) the previous night. A 
total volume of 50 ml of blood was drawn from each individual by venipuncture.  
First, a tube containing Ethylenediaminetetraacetic acid (EDTA) was filled and 
inverted five times immediately. These plasma samples were used for DNA 
extraction. Second, three gel tubes were filled, inverted five times immediately, let 
stand for 30 minutes for coagulation in room temp, centrifuge for 10-15 minutes at 
3800 rpm. Thus, the serum was tapped from the gel tubes to a collection tube and 
placed in a transport cylinder. These serum samples were used for storage and for the 
following metabolomics analysis. Serum samples for biochemical analysis were 
collected in the same way. 
Tubes were sent to Karolinska University Laboratory by overnight post where they 
were frozen at -80° C in liquid nitrogen until analysis. 
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In total, 12,591 individuals (55% women) participated by donating blood to the study, 
and by answering questionnaires about lifestyle and health. 
In study I, we included 6,558 unrelated individuals (only one twin per pair) with 
cardiovascular risk factors measurements available. 
In study II, we included in the analyses all genotyped twins with cardiovascular risk 
factors measurements available and without previous CHD events, resulting in 7,597 
individuals. 
Metabolomics was performed in a subsample of TwinGene. Specifically, we utilized a 
case-cohort design by selecting all the incident cases of coronary heart disease, type 2 
diabetes, ischemic strokes and dementia up to 31st December 2010 and a sub-cohort 
(controls) of 1,643 individuals (43% women). The subcohort was stratified on median 
age and sex, and for each of the four strata, we randomly selected a number of 
participants proportional to the corresponding number of cases. Thus, in study III we 
included the participants sampled in the sub-cohort and the incident CHD cases for a 
total of 1,670 individuals with cardiovascular risk factors measurements available and 
without previous CHD events at baseline.  
6.3 Swedish Twin Registry: SATSA 
The SATSA sample comprises all pairs of twins who indicated that they had been 
separated before the age of 11 and reared apart, and a sample of twins reared together 
matched on gender, date and county of birth [85]. SATSA twins aged 50 and older 
were invited to participate in in-person testing (IPT) sessions in which questionnaires 
including items concerning health-related behaviours (e.g. alcohol, tobacco, and 
dietary habits), cognitive tests and physical health measures were administrated. 
SATSA twins have been followed longitudinally with up to nine IPT sessions across 
24 years. In study II, samples for DNA extraction, lipid measurements and other 
cardiovascular risk factors from the third IPT (1992-1994) were used. The SATSA 
study was used in study II, in total, 435 individuals with cardiovascular risk factors 
measurements available and without previous CHD events were included in the 
analyses. 
6.4 Swedish Twin Registry: OCTO-Twin 
The OCTO-Twin sample included all twin pairs in Sweden aged 80 years or older in 
1991-1994 (i.e. birth years 1913 or earlier)	  [86]. Up to five waves of IPT sessions at 
two-year intervals were conducted on all living twins who agreed to participate, 
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irrespective of co-twin’s vital status. Blood samples for subsequent extraction of 
DNA were collected between the first and second IPT. Questionnaires were similar to 
the ones used in SATSA. Cardiovascular risk factors were measured at the first IPT 
(1991-1994).  The OCTO-Twin study was used in study II of this thesis, in total, 410 
individuals with cardiovascular risk factors measurements available and without 
previous CHD events were included in the analyses. 
6.5 Swedish Twin Registry: GENDER 
The GENDER sample included all living pairs of unlike-sex twins born between 1906 
and 1925 [87]. Surveys assessing health and other factors were sent to the twin pairs. 
A subset of this population-based sample aged 70-79 years completed IPT similar to 
those in SATSA and OCTO-Twin. Three waves of IPT sessions were carried out at 
four years intervals during 1995-2004. Blood samples for DNA extraction and 
cardiovascular risk factors were collected during the first IPT session (1995-1997). 
The GENDER study was used in study II of this thesis. In total, 421 individuals with 
cardiovascular risk factors measurements available and without previous CHD events 
were included in the analyses. 
6.6 Swedish Twin Registry: HARMONY 
All twins from the Swedish Twin Registry aged 65 and older were screened by 
telephone for cognitive dysfunction [88]. This included any surviving twins from the 
SATSA, OCTO-Twin, and GENDER studies described above. Among those 
screened, 11.5% were positive for suspicion of dementia and were referred for 
complete clinical evaluation and blood sampling by a physician or a nurse (1999-
2001). Once the preliminary IPT suggested dementia, the twin partner was also 
invited for an identical clinical work-up. In study II, 936 participants not recruited in 
SATSA, OCTO or GENDER with genotype information available were considered. 
The HARMONY study was used in study II. In total, 767 individuals with 
cardiovascular risk factors measurements available and without previous CHD events 
were included in the analyses. 
6.7 ULSAM 
Men born between 1920 and 1924 in Uppsala, Sweden were invited to participate at 
age 50 (N=2,841) in this longitudinal cohort study, which was started in 1970 [89]; 
81.7% (N=2,322) participated. Individuals were re-investigated at the ages of 60, 70, 
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77, 82 and 88 years. Information collected includes a medical questionnaire, blood 
pressure and anthropometric measurements, glucose tolerance test and 24-hour 
ambulatory blood pressure.  
At age 70, EDTA plasma, citrate plasma, serum and whole blood for DNA extraction 
were collected from fasting participants and stored at -70° C in liquid nitrogen until 
analysis. Additional EDTA plasma was collected during oral glucose tolerance test. 
EDTA plasma samples were used for the metabolomics profiling. 
In study II, we included in the analyses, all individuals genotyped at age 70 with 
cardiovascular risk factors measurements available and without previous CHD events, 
resulting in 981 individuals. 
In study III, 1,028 individuals with cardiovascular risk factors and metabolomics 
measurements available and without previous CHD events were included in the 
analyses. 
6.8 PIVUS 
PIVUS is a community-based study where all men and women at age 70 living in 
Uppsala, Sweden were invited to participate in 2001 [90]. The 1,016 participants 
(50% women) have been extensively phenotyped including measurements of 
endothelial function and arterial compliance, cardiac function and structure by 
ultrasound and magnetic resonance imaging, evaluation of atherosclerosis by 
ultrasound and magnetic resonance imaging, seven day food intake recordings, 
detailed electrocardiogram (ECG) analysis, cardiovascular autonomic function and 
body composition by dual-energy X-ray absorptiometry. 
Blood samples were drawn between 8 and 10 AM after an overnight fast. Plasma 
taken in EDTA-tubes was centrifuged, aliquoted and frozen within one hour. Serum 
was aliquoted and frozen within two hours. These samples were stored at -70° C in 
liquid nitrogen. Metabolomic profiling was performed on serum samples. The PIVUS 
study was used in study III. In total, 767 individuals were included in the analyses. 
6.9 UK Biobank 	  
UK Biobank recruitment took place between March 2007 and July 2010 via the UK 
National Health Service at 21 centres across England, Wales and Scotland [77]. All 
individuals aged 40-69 living within a reasonable travelling distance of an assessment 
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centre were asked to participate via postal invitation with a telephone follow-up. The 
overall response rate was 5.47 %.  
Participants completed a “whole-body” assessment of 90-min duration that included a 
computerized questionnaire on lifestyle and medical history as well as blood and 
urine collection, a verbal interview with a trained nurse and physical measures 
including blood pressure, arterial stiffness, eye measures, hand grip strengths, 
anthropometry, bone densitometry of heel, spirometry and ECG from exercise test. 
The UK Biobank study was used in study IV. In total, 498,103 participants were 
included in the analyses. 
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7  Results and discussion 
7.1 Prediction measures and sampling design 	  
The high cost of laboratory assays makes the ascertainment of new omics 
technologies in all participants of large epidemiological studies unfeasible. It is 
therefore important to use sampling designs to determine which samples to select. 
Study I investigates a particular aspect of this problem, that is, if prediction measures 
such as calibration, discrimination and reclassification can be calculated within 
traditional sampling designs and which sampling design is more appropriate to 
calculate such measures. 
Specifically, we considered two sampling designs, case cohort and nested-case 
control (described in section 4.3), and two sampling schemes for each design: 
1. Unstratified designs. For the case-cohort design, the sub-cohort is a random 
sample from the original cohort; for the nested case-control design, x controls are 
selected at random from individuals at risk at each case’s failure time. 
2. Stratified designs. For the case-cohort design, four strata (male or female and age 
higher or lower than the median) are considered and a number of participants 
proportional to the number of cases in each of these strata is randomly sampled 
from the original cohort. For each case in the nested case-control design, x 
controls at risk with the same sex and age (fine matching) are selected. 
 
Results 
We first compared the four combinations of sampling designs and sampling schemes 
for association with CHD in TwinGene. The gold standard was the association 
observed in the entire cohort. We found that both case-cohort and nested case-control 
designs gave more accurate results when stratified/matched sampling was used. 
Stratified case-cohort and matched nested case-control designs were comparable in 
terms of accuracy and efficiency of estimates; the unmatched nested case-control 
design was more efficient than the unstratified case-cohort design. 
Secondly, we evaluated which sampling design more accurately calculated the risk of 
a CHD event within three years. To account for the sampling process, the individual 
risk was calculated by reweighting the baseline hazard with appropriate weights. 
Overall, the estimated individual risk from the sampling designs was comparable to 
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that observed in the entire cohort, except for the matched nested case-control design, 
which resulted in biased estimates. 
Third, we compared sampling designs and whole cohort in terms of measures of 
discrimination (C-index), calibration (Grønnesby and Borgan goodness-of-fit test 
statistic) and reclassification (NRI). Overall, in the case-cohort designs and the 
unmatched nested case-control design, the estimates of the different prediction 
measures were similar to what was observed for the whole cohort, but the variability 
was higher. The C-index for the matched nested case-control design was lowest, 
underestimating the true value.  
 
Discussion 
Prediction measures can be calculated in a sampling design setting by using 
appropriate weights. Although this is straightforward for case-cohort designs where 
the subcohort is a random or stratified sample of the whole cohort, the appropriate 
weights for nested case-control designs are more complex as they are based on the 
inverse of the probability that a participant is ever selected as a control.  
The finely matched nested-case control design obtained biased estimates of the 
individual risk and, consequently, the prediction measures were unsatisfactory. That 
is, failing to take into account the appropriate weights results in an underestimation of 
the C-index and consequently an overestimation of the discriminative power 
introduced by the additional marker. 
More recently, it has been shown that is possible to obtain correct estimates of the 
individual risk from finely matched nested case control designs by using stratum-
specific baseline hazards (Dr. Agus Salim, personal communication). 
In conclusion, this study suggests that it is possible to calculate prediction measures 
from sampling designs and that the stratified case-cohort design is a reasonable choice 
both in terms of efficiency and simplicity in the calculation of prediction measures. 	  
7.2 Genetics and prediction of cardiovascular disease 	  
The utility of common genetic variants in primary prevention of cardiovascular 
disease has been subjected to several investigations [91, 92]. Overall, it has been 
suggested that there is not enough evidence for including genetics in current 
prediction models for cardiovascular disease [93]. Other studies have however 
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pointed out that useful levels of prediction may be approached with larger study 
samples [94].  
In study II, we investigate the association between several MGRSs and CHD and 
evaluate their potential clinical utility. Two main MGRS were considered: 
1. An overall MGRS obtained from 395 SNPs associated with CHD or CHD-related 
traits. 
2. A CHD-specific MGRS obtained from 46 SNPs that have been found associated 
with CHD by the CARDIoGRAMplusC4D consortium, which is the largest 
genome-wide association studies meta-analysis on CHD to date [95]. 
 
Results 
We first investigated the association between the MGRS and CHD after adjustment of 
established risk factors in 10,612 participants from six prospective studies 
experiencing 781 CHD events. Both the overall MGRS and the CHD-specific MGRS 
were highly significantly associated with CHD. Specifically, participants who were in 
the upper quartile of the distribution of the overall MGRS had 1.54 times [95% 
confidence interval (95% CI): 1.25-1.92] higher risk of CHD compared with 
individuals in the lowest quartile. 
Second, we studied discrimination and reclassification. The overall MGRS 
significantly improved risk classification beyond established FHS risk factors (NRI= 
4.2%), but the discrimination improvement was modest.  
Third, we evaluated the number of events prevented and the number of event-free life 
years saved if the CHD-specific MGRS was measured in addition to the established 
risk factors. That is, assuming a risk reduction of 20% for individuals treated with 
statins [96], the targeted assessment of the genetic risk score among intermediate risk 
subjects could help to prevent about four additional CHD events during a ten-year 
period, which corresponds to one avoided event for every 318 people screened. If the 
CHD-specific genetic score was measured in the entire study population, 3.15 event-
free life years per 1000 people screened would have been saved. 
 
Discussion 
The use of genetic profiling in primary prevention of CHD might improve allocation 
of patients to correct risk strata. A topical editorial [97] mentioning ours and other 
recent studies [98, 99] has highlighted how the prediction performances of genetic 
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risk scores are superior to those from other recently suggested biomarkers for 
prediction of cardiovascular disease (e.g. C-reactive protein, fibrinogen) [100] and 
wished for the translation of these findings in clinically meaningful action. 
Genetic profiling has some advantages compared with other biomarkers. For 
example, genetic markers need to be measured only once and are likely to be 
predictive throughout life enabling earlier primary prevention in high-risk individuals. 
Moreover, the genotyping cost has rapidity dropped in the past years making genetic 
markers potentially cost-effective. However, formal studies investigating this aspect 
are needed. Finally, only carefully designed randomized trials will be able to provide 
a convincing confirmation about the expected benefits of genetics scores for primary 
prevention. 
In conclusion, genetic information could be of some clinical value for prediction of 
CHD, although further studies are needed to address aspects such as feasibility, ethics, 
and cost efficiency of genetic profiling in the primary prevention setting. 
7.3 Metabolomics and cardiovascular disease 	  
The exploration of the metabolome holds a great potential to fuel the discovery of 
novel biomarkers of CHD. Such exploration has only become feasible in the past few 
years since technological advancements have allowed the measurements of hundreds 
of metabolites in thousands of samples. However, very few studies have performed a 
truly non-targeted metabolomics approach due to bioinformatics challenges and 
difficulties with the annotation of the metabolites.  
In study III, we aimed to investigate the association between metabolic features and 
CHD, and to integrate genetic and metabolomics analysis to delineate the underlying 
biological mechanisms and evaluate potential causal effects of the novel biomarkers. 
 
Results 
We first studied the association between circulating metabolites and incident CHD 
events. We identified four metabolites that were associated with CHD after 
adjustment for established cardiovascular risk factors in 1,028 ULSAM participants 
(No. of events=131) and replicated in 1,670 TwinGene participants (No. of 
events=282). All four metabolites were lipid-related species: Two 
lysophosphatidylcholines, one sphingomyelin and one monoglyceride. 
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Second, we studied the joint discrimination and reclassification properties of the four 
metabolites in TwinGene. We observed a significantly improved risk classification 
beyond established FHS risk factors (NRI= 9.2%), but the discrimination 
improvement was modest. 
Third, we explored the associations of the four novel metabolites with main 
cardiovascular risk factors, as well as with markers of oxidative stress, inflammation 
and subclinical CVD in additional 970 PIVUS participants. Lysophosphatidylcholines 
were negatively associated with BMI and with less evidence of subclinical CVD; a 
reverse pattern was observed for the monoglyceride. 
Fourth, we studied the association with established CHD-SNPs and performed a 
Mendelian randomization approach. Only the monoglyceride showed an enrichment 
of significant associations with CHD-associated SNPs and a weak, but positive causal 
effect, as suggested by Mendelian randomization analysis. 
 
Discussion 
Four metabolites were identified as promising biomarkers of CHD: Two 
lysophosphatidylcholines, one sphingomyelin and one monoglyceride. While not 
much is known about the involvement of sphingomyelins in the pathogenesis of CHD, 
lysophosphatidylcholines has been previously indicated by functional studies to have 
a pro-inflammatory and pro-atherogenic effect [101]. This is in contrast with what 
observed in this study. However, recent population-based studies have suggested a 
protective effect of lysophosphatidylcholines on cardiovascular risk [75, 102], 
diabetes [103] and Alzheimer's disease [104]. We are currently performing zebrafish 
experiments to further delineate the role of these metabolites in lipid deposition and 
atherosclerotic plaques formation. 
In conclusion, four lipid-related metabolites with evidence for clinical utility, as well 
as a causal role in CHD development were identified using a metabolomics approach. 
The use of animal models should help to further clarify the causal role of these 
metabolites. 
7.4 Prediction of five-year overall mortality 	  
It is an important public health priority and a central issue in clinical decision making 
to identify potential predictors of mortality, especially in the working age population. 
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Such predictors can be combined in a prediction score, which allows identification 
and risk stratification of individuals with reduced life expectancy.  
Large, contemporary prospective studies collecting a wide range of measurements are 
needed to reach these goals. In study IV of this thesis, we compared more than 600 
measurements of demographics, health and lifestyle with all-cause mortality and five 
cause-specific mortality categories. Moreover, we developed and validated a 
prediction score for five-year mortality using only self-reported information. 
 
Results 
We first studied the sex-specific association between 655 measurements and all-cause 
and cause-specific mortality in 498,103 UK Biobank participants experiencing 8,532 
deaths during a median follow-up of five years. We found that measures that can 
simply be obtained by verbal interview without physical examination were the 
strongest predictors of all-cause mortality. Self-reported health and walking pace were 
among the strongest predictors in both genders and across different causes of deaths.  
Second, we considered previously healthy individuals, by excluding those with a 
Charlson index greater than one. In this subgroup of individuals, smoking habits were 
the strongest category of mortality predictors.  
Third, we built, validated and calibrated a prediction score. We selected 13 and 11 
self-reported predictors for men and women, respectively, using a backward stepwise 
variable selection approach. Thus, we created a prediction model and validated it in 
the participants from the two Scottish centers, which were not used to develop the 
prediction score. The discrimination abilities were good (C-index 0.80 [95% CI 0.77-
0.83] for men and 0.79 [95% CI 0.76-0.83] for women). Finally, we calibrated our 
prediction score using UK life tables and census information so that it was 
representative of the entire UK population aged 40 to 70. 
 
Discussion 
The study provides an extensive analysis of predictors of mortality in a large, 
contemporary prospective cohort study. By ranking measurements in terms of their 
predictive abilities we could provide new insights about the relative importance, as 
well as reveal some unexpected associations.  
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The most predictive self-reported measurements were combined in a prediction score 
that could be used by laypersons to improve self-awareness of the health status, by 
clinicians to identify high patients to target with specific interventions and by 
governmental and health organizations to decrease the burden of certain risk factors. 
To calibrate the prediction model, an innovative strategy that used life tables and 
census information was used. This allowed to overcome some of the issues related to 
the generalizability of the study.  
Finally, all results were made available on an interactive website (www.ubble.co.uk) 
where it is possible to explore the observed associations in detail to generate new 
research hypotheses, and to calculate the biological age through an online 
questionnaire. 
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8 Future directions 
8.1 Sampling designs and big data 	  
With the advent of the ‘big-data’ era, one would expect to observe a growing interest 
in sampling designs. Instead, while much effort has been spent in developing 
strategies to optimize and parallelize computations, the research in sampling designs 
has remained limited to specialists in the field and failed to reach out to a larger 
audience.  
Abundance of exceedingly technical literature, lack of comprehensive reviews on the 
topic and failure to implement analytical methods in statistical software are all factors 
contributing to the general lack of translation. For example, in R, the only function 
available to obtain estimators for case-cohort designs is the cch function from the 
survival package. This function has several limitations, including the inability to 
handle time-dependent covariates. More recently, the survey package from Thomas 
Lumely has implemented more complex sampling designs, but the functions are not 
optimized for big datasets [105]. 	  
Furthermore, most of the current research focuses on the correct estimation of 
standard errors, while much less attention has been dedicated to measures of 
predictive performances of the model, which are central in the ‘big data’ paradigm. 
Indeed, it seems underappreciated the fact that a well-planned sampling design can 
deliver virtually identical information compared to the analysis conducted on the 
entire population, with the advantage of greatly reducing the computational burden. 
For example, sampling designs are routinely used in large population-based registries 
as an effective way to investigate epidemiological questions without the need to 
process the entire population [106-108].  
Software implementation, translational research and better communication with 
researchers outside the narrow research field are ways to move forward research and 
applications of sampling designs.  
8.2 Prediction models: Thinking outside the box 	  
Newly discovered markers are often evaluated in addition to established risk factors 
for their ability to improve current prediction models. Although this is certainly a 
valid approach, it comes with the assumption that current risk factors are optimal 
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predictors. One can argue that this is not the case given that current prediction models 
have been developed in sample sizes that were smaller than those currently available 
and included a limited number of potential predictors.  
With the advent of several new large initiatives in different countries, collecting 
baseline information from hundreds of thousands of individuals [77, 78], there is now 
room to rethink current prediction models. Novel untargeted screening of large risk 
factors collections can be used to identify new predictors. Such screening should 
include also those risk factors that are not causatively related with the outcome of 
interest and should identify uncorrelated risk factors with the aim to improve 
prediction. 
Variable selection approaches using penalized likelihood can be use to achieve these 
goals and they have been shown to be more appropriate than traditional stepwise 
selection approaches [109, 110].	  	  
Moreover, with the widespread use of informatics technologies among patients and in 
the clinic, it is possible to start to think about non-traditional modelling strategies 
accounting for complex interactions and non-linear effects that can be directly 
integrated in online calculators and without the need to relay on printed score charts. 
For example, ensemble algorithms derived from the machine-learning field, has been 
shown to perform better than traditional linear models alone in epidemiological 
studies [111]. 
Finally, prediction models for the same outcome are often developed on different 
populations, hampering the comparison of their predictive performances. Open risk 
prediction competitions, such as the DREAM Challenges [112], can be used to obtain 
an objective comparison of different prediction models in the same population, to 
increase the generalizability and the transparency of the results and to motivate the 
researchers to think ‘outside the box’ in terms of statistical modelling. 
Evidence-based medicine will see an increase use of prediction models as a way to 
deliver personalized and cost-effective care. There is a need to rethink current 
prediction models in the light of available methodologies and new large-scale efforts. 
Prediction competitions and faster implementation of novel prediction models in 
clinical guidelines are ways to motivate researchers to take on the challenge of 
delivering high-quality and innovative research in this field.  
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8.3 Clinical utility assessment: Understanding the context 	  
The original NRI paper [31], published in 2008, has been cited more than 2,200 times 
and has generated a plethora of comments and critics [33, 113-115]. Researchers have 
been using this measure to claim the clinical utility of new markers for cardiovascular 
disease [116], breast cancer [117] and diabetes [118]. However, several misuses of 
this measure have been reported [119], especially in investigations of diseases where 
no clinically relevant risk categories are available. These critics have sorted the 
paradoxical effect of having authors explicitly mentioning the lack of NRI use in their 
paper [120, 121].  
Flaws in claims of clinical utility are not new. In a lucid paper [122], Tzoulaki and 
colleagues have examined 79 studies evaluating improvement in predictive 
performance when predictors where added to the Framingham risk score.  They found 
that although the majority of examined studies claimed additional predictive value 
beyond what the Framingham risk score could achieve, most had flaws in their 
design, analyses, and reporting. Several issues where related to the incorrect use of 
the AUC measure. 
Taken together, these observations highlight the need for a better definition of which 
measures should be considered before claiming clinical utility. Leading experts in the 
field have published guidelines on how to evaluate predictive performance of new 
markers [123, 124], but it seems that most of these advises are not translated in 
practice. But most importantly, even in well-conducted studies, it is not clear what 
should be the natural step after reporting evidence of improved predictive 
performances. 
It is therefore reasonable to argue that current measures of calibration, discrimination 
and reclassification are not directly translatable into clinical actions. Instead, these 
measures should mostly serve as screening tools to determine which markers should 
be taken forward to formal health economic evaluations and, when possible, to 
clinical trials.   
Thus, it is important to conceptualize these measures within a broader directional 
framework that goes from marker discovery to introduction in clinical practice. They 
occupy a central position, following marker discovery but before appropriate 
investigations of clinical utility. Lacking of understanding this concept might result in 
wrong claims. 
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8.4 Integration of omics technologies using a vertical approach 
 
Genome-wide association studies have paved the way in terms of statistical rigour, 
reproducibility, agnostic believes and data-sharing. Similar approaches have been 
used to interrogate other biological layers, such as methylation and metabolic profiles, 
and have been proved to be successful in discovering novel associations [103, 125]. 
These horizontal approaches are relatively easy to implement and have the advantages 
to provide new discoveries with a high grade of reproducibility.  
However, the translation of such findings into mechanistic insights, clinically relevant 
results and drug discovery is more likely to be achieved by integrating different omics 
layers including in vivo and in vitro follow-up.  
Such vertical approach, as opposed to the horizontal approach of single omics 
screening, should be able to prioritize pathways of interest by both data-driven 
discovery and integration of external information.  
While horizontal screenings are hypothesis-free and relies only on information 
derived from the data, an integrative vertical approach needs to take into account 
external information regarding the biological nature of the interaction between omics 
layers.  
This information can be partially obtained by integrating data provided by large 
consortia, such as GTEx [126], ENCODE [127] and the Human Protein Atlas [128]. 
Moreover, information from previous horizontal screenings (e.g. summary statistics 
from GWAS meta-analyses) should also be included in order to prioritize specific 
pathways of interest and reduce the search space. 
The complexity of the vertical approaches is far higher than that of horizontal 
approaches and several improvements need to be made. 
First, statistical methods able to integrate different layers of omics data and to handle 
constrains of biological nature are needed. A recently proposed method goes in this 
direction by getting inspiration from the field of geostatistics [129]. However, no 
external information can be yet integrated in this model.  
Second, deeply phenotyped studies need to be collected. Repeated measurements 
should also be assessed in order to estimate the inherent variability due to 
environment influence and physiological states. Moreover, new ways to collect 
tissues other than blood and urine should be explored. 
	  	   44	  
Finally, high-throughput in vivo and in vitro experiments need to be conducted in a 
fast and cost-effective manner to validate findings and allow for direct therapeutic 
translation.  
In conclusion, horizontal and vertical approaches should be combined to discover new 
clinically and therapeutically relevant targets. The latter approach poses several 
challenges that need to be addressed by future research. 
 
8.5 Data sharing and privacy: Opportunities and challenges 	  
Data sharing is of enormous importance in modern science. First, it allows the access 
by a larger scientific audience to resources that would have otherwise been available 
to few researchers. Second, it increases the pace of scientific discoveries by allowing 
data to be used for purposes other than what they have been collected. Third, it allows 
the scientific community to scrutinize the results from a study, thus increasing the 
validity of its findings. 
For example, using publically available microarray experiments researchers have 
recently identified a promising therapeutic target for diabetes [130]. Data sharing 
have also stimulated a wealth of statistical methods specifically designed to handle 
aggregate data, such as summary statistics from GWAS [131].  
There are numerous sources of publically available data. Omics data repositories have 
been created in parallel with the increased demand for data sharing from scientific 
journals, as a way to improve reproducibility and transparency. Data from clinical 
trials, independently if they have been successful or not, are increasingly being made 
publically available allowing the possibility to use this data for new and unexpected 
research questions [132]. Large initiatives such as the Global Alliance for Genomics 
and Health have been created to make possible the large-scale collection of data on 
genome sequencing and clinical outcomes within a common framework and using 
standardized methodology. Finally, for profit organizations such as 23andMe have 
recognized the importance of sharing their data with the scientific community as a 
way to stimulate innovative ideas and identify new commercially viable targets. 
On the other side, with the increased availability of medical data on the web, privacy 
concerns have been raised. For example, anonymized genomics information can be 
combined with publically available genealogy databases to obtain personal 
information (e.g. patient’s surname) without patient’s consent [133]. Similarly, it has 
	  	   45	  
been shown that DNA of individuals can be identified from complex mixtures of 
information, for example from GWAS summary statistics [134].  
It is therefore important to engage the scientific community and the general public in 
a rational discussion about the risks and benefits of having medical and genetics 
information publically available. As a way to achieve this goal, scientists should start 
by strengthening their ability to communicate scientific findings to laypersons, for 
example by employing tools that make results interpretable by a broader community 
(e.g. interactive websites, mobile applications).  
In conclusion, data sharing is beneficial to the scientific community. Improved 
communication and a clear, balanced informed consent are key elements to uphold 
this benefit together with a long-lasting credibility in the general public. 
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